Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling
Metrics: PDF 1866 views | HTML 1347 views | ?
Qiong Xu1,2,*, Hai-Xu Xu1,*, Jin-Ping Li2, Song Wang2, Zheng Fu1,2, Jing Jia2, Li Wang1,2, Zhi-Feng Zhu2, Rong Lu1,2, Zhi Yao1
1Department of Immunology, Tianjin Medical University, Tianjin, China
2Tianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, China
*These authors contributed equally to this work
Zhi Yao, email: firstname.lastname@example.org
Rong Lu, email: email@example.com
Keywords: cancer stem cells, hepatocellular carcinoma, GDF15, metastasis, tumorigenesis
Received: November 25, 2016 Accepted: January 27, 2017 Published: February 09, 2017
Cancer stem cells in liver cancer are thought to be responsible for tumor recurrence and metastasis. However, the factors that mediate this mechanism have yet to be completely elucidated. In this study, we isolated CD13+CD44+ sphere cells (SCs) derived from liver cancer tissues and SK-Hep-1 cells, which possessed cancer stem cell-like properties. Through cytokine array analysis, growth differentiation factor 15 (GDF15) was significantly increased in SCs. Clinical data showed GDF15 was overexpressed in liver cancer tissues and was positively related to pathological grading. GDF15 knockdown significantly inhibited the growth and metastasis of SCs through AKT/GSK-3β/β-catenin pathway suppression. Moreover, a PI3K inhibitor LY294002 inhibited AKT/GSK-3β/β-catenin pathway activated by GDF15 and attenuated GDF15-induced proliferation, colony formation and invasion of SCs. Conclusion: Our studies suggest that CD13+CD44+ SCs may represent a subset of LCSCs. GDF15 promotes the growth and metastasis of SCs by activating AKT/GSK-3β/β-catenin signaling pathway. Promisingly, GDF15 could be considered as a potential therapeutic target in liver cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.